KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511714-20-00

Acronym

NMSG25/16

Enrollment

Registered

2024-10-04

Start date

2018-01-30

Completion date

Unknown

Last updated

2025-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Proportion of PET-CT positivity after standard first line therapy, Change from PET-CT positivity to PET-CT negativity after 4 cycles of KRd consolidation.

Detailed description

MRD negativity by 8-colour EuroFlow after 4 cycles of KRD consolidation., Safety, Overall response rate, Progression-free survival (PFS), Time to next treatment (TTNT), Overall survival (OS), Quality of life during and after KRD consolidation

Interventions

DRUGLENALIDOMIDE

DRUGKyprolis 60 mg powder for solution for infusion

DRUGDEXAMETHASONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of PET-CT positivity after standard first line therapy, Change from PET-CT positivity to PET-CT negativity after 4 cycles of KRd consolidation.	—

Secondary

Measure	Time frame
MRD negativity by 8-colour EuroFlow after 4 cycles of KRD consolidation., Safety, Overall response rate, Progression-free survival (PFS), Time to next treatment (TTNT), Overall survival (OS), Quality of life during and after KRD consolidation	—

Countries

Denmark, Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026